Skip to main content
VERICI DX PLC logo

VERICI DX PLC — Investor Relations & Filings

Ticker · VRCI ISIN · GB00BM8HZD43 LEI · 213800FI5WE4FVQ3G645 IL Real estate activities
Open in API
Filings indexed 189 across all filing types
Latest filing 2023-02-27 Regulatory Filings
Country GB United Kingdom
Listing IL VRCI

About VERICI DX PLC

https://www.vericidx.com/

Verici Dx is an immuno-diagnostics company developing and commercializing a suite of proprietary tests for the kidney transplant market. The company's platform utilizes artificial intelligence-assisted transcriptomic analysis of RNA signatures to provide data-driven insights to clinicians. These tests are designed to decipher the body's immune response and other biological signals, enabling personalized risk assessment for organ injury, rejection, and graft failure. The goal is to assist clinicians in medical management throughout the transplant process, from pre-transplant to late-stage care, ultimately aiming to improve patient outcomes and long-term graft survival.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 99% confidence The document is very short (1914 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing the 'RNS Number' and stating that this information is provided by RNS, the news service of the London Stock Exchange, approved by the Financial Conduct Authority (FCA). This is a brief, specific regulatory update that does not fit the definitions for major reports (10-K, IR, ER) or specific corporate actions (DIV, CAP, MANG). Since it is a general regulatory announcement disseminated via the RNS system, and it is not announcing the publication of a larger report (which would suggest RPA), the most appropriate classification is the general regulatory filing category. Code RNS (Regulatory Filings) is the best fit for miscellaneous, short regulatory notices.
2023-02-27 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification filed via RNS (Regulatory News Service) concerning a transaction by a person discharging managerial responsibilities (PDMR). Specifically, it details the 'Grant of options' to a Non-Executive Director (Dr Lorenzo Gallon) over the company's ordinary shares. This type of insider transaction reporting, mandated by regulatory bodies, falls directly under the category of Director's Dealing (DIRS). Although it is an RNS filing, the specific content is highly indicative of DIRS, which is a more precise classification than the general RNS fallback.
2022-12-07 English
Correction: Holding(s) in Company
Major Shareholding Notification Classification · 98% confidence The document is identified by the RNS Number (3453I) and contains a 'TR-1: Standard form for notification of major holdings - amendment'. This form is used to report changes in significant share ownership, specifically detailing the percentage of voting rights held by Unicorn Asset Management Limited/Unicorn AIM VCT plc. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content is a major holding notification, making MRQ the most precise classification over the general RNS fallback.
2022-12-01 English
Product rebranding as Tutivia™
Regulatory Filings Classification · 100% confidence The document is identified by the 'RNS Number' header and contains the label 'RNS REACH'. The text explicitly states, 'Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain.' Furthermore, it concludes by stating, 'Reach is a non-regulatory news service.' This indicates the document is a general corporate announcement that is not a mandatory regulatory filing like a 10-K or an Earnings Release (ER). Since it is a non-regulatory announcement distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS), which serves as the fallback for miscellaneous, non-core regulatory announcements, especially those explicitly marked as non-regulatory news releases.
2022-10-03 English
Half-year Report
Interim / Quarterly Report Classification · 100% confidence The document is a 'Half-year report' for Verici Dx plc for the period ended 30 June 2022. It contains detailed operational highlights, financial highlights (including EBITDA loss and cash balance), a Chairman's statement, and a CEO's report. It provides substantive financial data and analysis for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2022
2022-09-07 English
Positive results for Clarava from validation study
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated 06 September 2022. It announces positive clinical validation study results for a diagnostic test (Clarava™) and mentions that further updates will be provided in the 'interim results announcement, which is due to be released on 7 September 2022.' The text explicitly states that the information is deemed inside information and is being published via a Regulatory Information Service (RNS), making it a regulatory announcement. Since it is an announcement about clinical progress and upcoming financial results, but not the financial results themselves (which are due the next day), and it is distributed via RNS, it fits best under the general 'Regulatory Filings' category (RNS) as a specific corporate update, rather than a specific financial report like ER or IR. It is not a short announcement pointing to a full report, but the report itself is a clinical/business update.
2022-09-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.